PD-1 Blockade with Nivolumab-Controlled Epstein–Barr Virus Infection and Associated Haemophagocytic Lymphohistiocytosis: a Case Report
Lihua Dong,Junjie Liu,Peng Zu,Xia Gao,Jianguang Du,Y.S. Wang,Youfu Li
DOI: https://doi.org/10.1016/j.cmi.2019.06.010
IF: 13.31
2019-01-01
Clinical Microbiology and Infection
Abstract:In July 2013, a 24-year-old man was admitted complaining of a stuffy nose for 3 months. A computed tomography (CT) scan of his whole body showed a left nasal mass (Fig. 1C). Pathological examination of the nasal mass indicated a typical presentation of NK/T-cell lymphoma (NKTCL) with extensive tissue necrosis and a large amount of inflammatory cell infiltration. Immunohistochemical staining revealed that the tumour cells were positive for CD2, CD56, granzyme B, CD3, Ki-67 (60%), and programmed death ligand-1 (PDL1) (80%), but negative for CD20 and programmed death-1 (PD1) (Fig. 1A,B). Epstein–Barr virus- (EBV-)encoded small RNAs (EBERs) were positive with hybridization in situ, whereas the EBV DNA copy number in plasma was undetectable. Bone-marrow aspiration and biopsy were normal. The patient was diagnosed with NKTCL, nasal type with stage IE, and received six cycles of L-DICE regimen chemotherapy (asparaginase, dexamethasone, ifosfamide, cisplatin, etoposide) following a dose of 52 Gy local irradiation with intensity-modulated radiation therapy (IMRT). According to Cheson criteria a complete remission (CR) was achieved (Fig. 1D). The patient presented again with high fever in March 2017. Laboratory tests showed severe pancytopenia, hypertriglyceridaemia, elevated ferritin and abnormal coagulation function. EBV DNA copy number was 2.27 × 105 copies/mL in peripheral plasma, the level of interferon-γ (IFN-γ) was 427 ng/L, and interleukin-2 (IL-2) was 3926 U/mL in peripheral blood. The soluble CD25 (sCD25) level was 7800 pg/mL (normal range <6400 pg/mL). Haemophagocytic histiocytes without lymphoma cells were found through marrow aspirate (1%). Flow cytometry assays showed that there was no abnormality in the marrow and peripheral blood. Whole-body enhanced CT scan revealed that there were no abnormalities (Fig. 1E). The patient was diagnosed with haemophagocytic lymphohistiocytosis (HLH) and administered etoposide combined with dexamethasone (core agents of HLH 2004) [[1]Henter J.I. Horne A. Arico M. Egeler R.M. Filipovich A.H. Imashuku S. et al.HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Pediatr Blood Canc. 2007; 48: 124-131https://doi.org/10.1002/pbc.21039Crossref PubMed Scopus (3220) Google Scholar]; however, the HLH gradually worsened with severe multiorgan dysfunction. The complete blood counts showed a white blood cell count (WBC) of 0.08 × 109/L, haemoglobin (HB) of 61 g/L, and a platelet count (PLT) of 9 × 109/L. Triglyceride levels were 2.29 mmol/L (normal range 0–1.5 mmol/L), and serum ferritin level was 13064 ng/mL (normal range 13–150 ng/mL). The IFN-γ and IL-2 levels were 731 ng/L and 5404 U/mL. The number of EBV DNA copies increased to 1.62 × 106 copies/mL. sCD25 level was 12 806 pg/mL. The patient consented to receiving nivolumab 200 mg every 3 weeks (based on its efficacy in clinical trial for advanced melanoma [[2]Robert C. Ribas A. Wolchok J.D. Hodi F.S. Hamid O. Kefford R. et al.Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.Lancet. 2014; 384: 1109-1117https://doi.org/10.1016/S0140-6736(14)60958-2Abstract Full Text Full Text PDF PubMed Scopus (1432) Google Scholar] and refractory/relapsed NKTCL in China). The fever rapidly declined, and the patient's blood cell count and serum biochemistry values gradually improved in the first cycle. Multiple skin papules and fever occurred for 2 h during the first infusion of nivolumab; these were controlled with calcium gluconate. After the second course of nivolumab, lymphocyte subtype analysis showed that T cells and NK cells made up 89.6% (normal range, 62.1–86%) and 8.8% (normal range, 6.0–23.1%) of total lymphocytes, respectively, and that CD4+ T cells and CD8+ T cells made up 32% (normal range, 30.1–52.8%) and 56.2% (normal range, 19.7–40.6%) of T lymphocytes, respectively. EBV DNA was undetectable. The IFN-γ and IL-2 levels were reduced to 19.8 ng/L and 174 U/mL, respectively. Autologous haematopoietic stem-cell transplantation was performed on the patient following two cycles of nivolumab. At the time of submission of this manuscript the patient has been alive and well for 21 months after PD-1 blockade treatment. Our patient achieved CR during first-line chemotherapy; however, the number of circulating EBV DNA copies increased during clinical follow-up, which gave rise to HLH. Some potential approaches to refractory EBV-related HLH have been reported, including anti-TNF-a monoclonal antibody [[3]Henzan T. Nagafuji K. Tsukamoto H. Miyamoto T. Gondo H. Imashuku S. et al.Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis.Am J Hematol. 2006; 81: 59-61https://doi.org/10.1002/ajh.20462Crossref PubMed Scopus (102) Google Scholar], antithymocyte globulin-based therapy [[4]Mahlaoui N. Ouachee-Chardin M. de Saint Basile G. Neven B. Picard C. Blanche S. et al.Immunotherapy of familial hemophagocytic lymphohistiocytosis with antithymocyte globulins: a single-center retrospective report of 38 patients.Pediatrics. 2007; 120: e622-e628https://doi.org/10.1542/peds.2006-3164Crossref PubMed Scopus (183) Google Scholar], CD19/CD3-bispecific T-cell-receptor-engaging antibody [[5]Teachey D.T. Rheingold S.R. Maude S.L. Zugmaier G. Barrett D.M. Seif A.E. et al.Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Blood. 2013; 121: 5154-5157https://doi.org/10.1182/blood-2013-02-485623Crossref PubMed Scopus (428) Google Scholar], anti-CD25 antibody [[6]Olin R.L. Nichols K.E. Naghashpour M. Wasik M. Shelly B. Stadtmauer E.A. et al.Successful use of the anti-CD25 antibody daclizumab in an adult patient with hemophagocytic lymphohistiocytosis.Am J Hematol. 2008; 83: 747-749https://doi.org/10.1002/ajh.21236Crossref PubMed Scopus (53) Google Scholar], a rituximab-containing regimen to eliminate EBV-infected B lymphocytes [[7]Chellapandian D. Das R. Zelley K. Wiener S.J. Zhao H. Teachey D.T. et al.Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens.Br J Haematol. 2013; 162: 376-382https://doi.org/10.1111/bjh.12386Crossref PubMed Scopus (145) Google Scholar], anti-CD52 antibody [8Marsh R.A. Allen C.E. McClain K.L. Weinstein J.L. Kanter J. Skiles J. et al.Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab.Pediatr Blood Canc. 2013; 60: 101-109https://doi.org/10.1002/pbc.24188Crossref PubMed Scopus (201) Google Scholar, 9Strout M.P. Seropian S. Berliner N. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.Nat Rev Clin Oncol. 2010; 7: 415-420https://doi.org/10.1038/nrclinonc.2010.40Crossref PubMed Scopus (72) Google Scholar], Janus kinase 1/2 (JAK1/2) inhibitor [[10]Maschalidi S. Sepulveda F.E. Garrigue A. Fischer A. de Saint Basile G. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.Blood. 2016; 128: 60-71https://doi.org/10.1182/blood-2016-02-700013Crossref PubMed Scopus (126) Google Scholar] and an L-DEP regimen [[11]Wang J. Wang Y. Wu L. Zhang J. Lai W. Wang Z. PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis.J Hematol Oncol. 2016; 9: 84https://doi.org/10.1186/s13045-016-0317-7Crossref Scopus (31) Google Scholar]. PD-1 belongs to the family of CD28/CTLA-1 receptors, and is expressed in activated CD4 and CD8 T cells. PD-1 binding with its ligand PD-L1 can inhibit the proliferation of activated T cells in peripheral tissues and lead to depletion of T cells and immune deficiency [12Chang C.H. Qiu J. O'Sullivan D. Buck M.D. Noguchi T. Curtis J.D. et al.Metabolic competition in the tumor microenvironment is a driver of cancer progression.Cell. 2015; 162: 1229-1241https://doi.org/10.1016/j.cell.2015.08.016Abstract Full Text Full Text PDF PubMed Scopus (1683) Google Scholar, 13Chen B.J. Chapuy B. Ouyang J. Sun H.H. Roemer M.G. Xu M.L. et al.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.Clin Canc Res. 2013; 19: 3462-3473https://doi.org/10.1158/1078-0432.CCR-13-0855Crossref PubMed Scopus (611) Google Scholar]. The latent membrane protein 1 (LMP 1) of EBV can upregulate PD-L1 expression through activating the MAPK/NF-κB and JAK/STAT pathways [14Bi X.W. Wang H. Zhang W.W. Wang J.H. Liu W.J. Xia Z.J. et al.PD-L1 is upregulated by EBV-driven LMP1 through NF-kappaB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.J Hematol Oncol. 2016; 9: 109https://doi.org/10.1186/s13045-016-0341-7Crossref PubMed Scopus (168) Google Scholar, 15Green M.R. Rodig S. Juszczynski P. Ouyang J. Sinha P. O'Donnell E. et al.Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.Clin Canc Res. 2012; 18: 1611-1618https://doi.org/10.1158/1078-0432.CCR-11-1942Crossref PubMed Scopus (512) Google Scholar]. Thus, PD-1 blockade may restore T-cell immune function, resulting in the removal of EBV-infected mononuclear cells and overactivated macrophages [[15]Green M.R. Rodig S. Juszczynski P. Ouyang J. Sinha P. O'Donnell E. et al.Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.Clin Canc Res. 2012; 18: 1611-1618https://doi.org/10.1158/1078-0432.CCR-11-1942Crossref PubMed Scopus (512) Google Scholar]. Kwong et al. reported seven patients with refractory and relapsed NKTCL treated with PD-1 blockade, including five of seven patients with HLH. EBV DNA load was undetectable in five of seven patients after one cycle of PD1 blockade treatment. In short, PD-1 blockade might restore the imbalanced immunological function and control EBV infection and EBV-associated HLH. The adverse effects were modest. The efficacy and safety of PD1 blockade in EBV infection and EBV-associated HLH should be further explored. All authors report no conflicts of interest relevant to this article. No external funding was received for this study. Dong LH, Liu J, Zu P are the co-first authors.